



October 30, 2013

## **MannKind Announces FDA Acknowledgement of Resubmission of New Drug Application for AFREZZA**

VALENCIA, Calif.--(BUSINESS WIRE)--Oct. 30, 2013-- **MannKind Corporation (Nasdaq: MNKD)** today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of a New Drug Application (NDA) for AFREZZA<sup>®</sup> (insulin human [rDNA origin]) Inhalation Powder. The FDA considered the updated NDA to be a complete class 2 response to its Complete Response Letter issued in January 2011 and assigned a user fee goal date of April 15, 2014.

### **About MannKind Corporation**

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. Its lead product candidate, AFREZZA<sup>®</sup>, has completed Phase 3 clinical trials. MannKind maintains a website at [www.mannkindcorp.com](http://www.mannkindcorp.com) to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

Source: MannKind Corporation

#### Company Contact:

MannKind Corporation

Matthew Pfeffer

Chief Financial Officer

661 775-5300

[mpfeffer@mannkindcorp.com](mailto:mpfeffer@mannkindcorp.com)

or

Media Inquiries:

MCS Healthcare Public Relations

Laura De Zutter or Jeff Hoyak

800 477-9626

[jeffh@mcspr.com](mailto:jeffh@mcspr.com)

[laurad@mcspr.com](mailto:laurad@mcspr.com)